News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Says Medicis’ 510(k) Application to Market LIPOSONIX Does Not Provide Sufficient Data
July 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
July 6 (Reuters) - Medicis Pharmaceutical Corp (MRX.N) said health regulators indicated in a letter last week that data in its current filing for marketing approval of its body sculpting device, LipoSonix, was not sufficient.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Approvals
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
November 19, 2026
·
3 min read
·
Heather McKenzie
Insights
The untapped potential of drug repurposing
November 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Approvals
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
November 18, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
November 18, 2026
·
3 min read
·
Annalee Armstrong